Incidence and Outcome of Male Breast Cancer: An International Population-Based Study

Miao, Hui; Verkooijen, Helena M.; Chia, Kee‐Seng; Bouchardy, Christine; Pukkala, Eero; Larønningen, Siri; Mellemkjær, Lene; Czene, Kamila; Hartman, Mikael

doi:10.1200/jco.2011.36.8902

Cited by 201 publications

(202 citation statements)

References 26 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…(Kaushik et al, 2014) Most Western studies have reported a 5 year OS of greater than 60% whereas results of Asian and African countries have shown a 5 year OS ranging from 40-60%. (Giordano et al, 2004;Miao et al, 2011;Shah et al, 2012;Sedighi et al, 2013) Our 5 year OS was 61.1% which was consistent with most of the South Asian studies as well as Western studies.…”

Section: Discussionsupporting

confidence: 85%

“…This can be attributed to factors such as lack of screening mammography and public awareness. (Giordano et al, 2004;Miao et al, 2011;Shah et al, 2012;Kaushik et al, 2014) The average age at diagnosis in our population was 52 years with 7 of our patients falling in the age group 50 to 55. This was 5 years younger than the age of diagnosis of women with FBC in Pakistan.…”

Section: Discussionmentioning

confidence: 60%

“…This has led to the conclusion that public awareness of the disease and screening may help in diagnosing this disease at an earlier age and a lower stage and hence lead to improved survival rates. (Miao et al, 2011;Kaushik et al, 2014) In conclusion, the main purpose of our study was to analyze the data available on MBC in a Pakistani hospital and compare it to the already existing excellent but limited data from both Asian as well as Western studies. We concluded that MBC may have a slow increase in incidence but is still considered a rare disease globally.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan

Jamy

Rafiq²,

Laghari³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

States has shown a significant increase in the incidence of MBC whereas a steady low rate has been observed in European studies. (Kaushik et al., 2014) There is still a paucity of randomized controlled trials and treatment for MBC is based on treatment for FBC.The general variation of MBC across the globe is similar to FBC with higher rates in North America and Europe and lower rates in Asia. (Chikaraddi et al., 2012;Kaushik et al., 2014) Materials and MethodsThis retrospective review was carried out at The Aga Khan University Hospital (AKUH) in Karachi, Pakistan. Approval was obtained from the ethics committee at AKUH. Files with ICD code 175 (Malignant neoplasm of male breast) were retrieved from patient medical records. A total of 19 patients with MBC were seen at our institute between January 1986 and December 2009. One patient with missing records was excluded from the study. Data from 18 files were reviewed and analyzed.The variables studied were age at diagnosis, comorbid conditions, presenting signs and symptoms (breast lump, erythema, nipple discharge and axillary lymphadenopathy), family history of breast cancer, smoking history, diagnostic modality, histopathology including hormonal work up, TNM staging, treatment

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan

Jamy

Rafiq²,

Laghari³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Breast cancer mortality among women has declined during the last decades because of improvements in diagnostic procedures and treatment, but the corresponding observation has not been made in male breast cancer. 1 Recent studies have indicated that males have a poorer survival than females, despite having received adjuvant treatment to the same extent. 2,3 In addition, studies on transcriptional and genomic levels have revealed important molecular differences between male and female breast cancer.…”

mentioning

confidence: 99%

High proliferation is associated with inferior outcome in male breast cancer patients

et al. 2013

View full text Add to dashboard Cite

Assessment of proliferation is important in female breast cancer and individual treatment decisions are based upon its results, especially in the luminal subgroups. Gene expression analyses fail to group male breast cancer into the intrinsic subgroups previously established in female breast cancer. Even though proliferation has been shown to divide male breast cancer into molecular subgroups with different prognoses, the clinical importance of proliferation markers has not yet been elucidated. Previous studies in male breast cancer have demonstrated contradictory results regarding the prognostic impact of histological grade and Ki-67, parameters strongly associated with proliferation. The aim of the present project was to study proliferation in male breast cancer by assessing other proliferation-related markers viz. cyclins A, B, D1 and mitotic count. A total of 197 male breast cancer cases with accessible paraffin-embedded material and outcome data were investigated. Immunohistochemical stainings were performed on tissue microarrays. Kaplan-Meier estimates and the Cox proportional regression models were used for survival analyses with breast cancer death as the event. The subset of patients with high expression of cyclin A (hazard ratio (HR) 3.7; P ¼ 0.001) and B (HR 2.7; P ¼ 0.02) demonstrated a poorer survival. Furthermore, high mitotic count was associated with an increased risk of breast cancer death (HR 2.5; P ¼ 0.01). In contrast, cyclin D1 overexpression was predictive of better breast cancer survival (HR 0.3; P ¼ 0.001). In conclusion, high levels of cyclin A and B expression and an elevated mitotic count result in a two to threefold higher risk for breast cancer death, whereas cyclin D1 overexpression halves the risk. The clinical utility of these proliferation markers needs further elucidation. Modern Pathology (2013) 26, 87-94; doi:10.1038/modpathol.2012.145; published online 24 August 2012 Keywords: breast cancer; immunohistochemistry; male Male breast cancer represents 0.6% of all breast cancer and because of its rarity, specific treatment guidelines are lacking. Thus, male patients are treated according to the guidelines for female breast cancer. Breast cancer mortality among women has declined during the last decades because of improvements in diagnostic procedures and treatment, but the corresponding observation has not been made in male breast cancer. 1 Recent studies have indicated that males have a poorer survival than females, despite having received adjuvant treatment to the same extent. 2,3 In addition, studies on transcriptional and genomic levels have revealed important molecular differences between male and female breast cancer. In a recent study, Johansson et al 4 performed gene expression analyses in male breast cancer and concluded that male breast cancer tumors could not be classified into the intrinsic subtypes previously established in female breast cancer. In line with these data, comparative genomic hybridization demonstrated significant differences regarding DNA aberrations com...

show abstract

“…Other studies reported that when matched by stage and age, men with breast cancer appeared to have a comparable or better prognosis than women (48). However, perhaps due to poor awareness of the disease and diagnostic delays, several studies argued that MBC with higher stage tumors and had a poorer overall prognosis (49).…”

Section: Discussionmentioning

confidence: 99%

The Management and Outcomes of Male Breast Cancer

Uslukaya

Gümüş

et al. 2016

J Breasth Health

View full text Add to dashboard Cite

Objective: Due to a lack of sufficient data, the treatment protocols for male breast cancer are usually the same as those used for female breast cancer. The aim of the current study was to present our clinical experience with male breast cancer. Materials and Methods:The records of 37 patients who were treated for male breast cancer in our hospital between 2004 and 2014 were reviewed retrospectively. The data of patients were recorded and analyzed.Results: The mean age of the patients was 63.03±12.36 years. Thirty-three patients (89.2%) had invasive ductal carcinoma, two (5.4%) had ductal carcinoma in situ, and two had invasive lobular carcinoma (5.4%). The most common molecular subtype was luminal A (17 cases, 45.9%). Twentynine patients with male breast cancer underwent mastectomy and two underwent breast conserving surgery. Axillary lymph node dissection was performed in 25 patients. The most common surgical procedure was modified radical mastectomy. Distant metastases were present in 17 (45.9%) patients. Overall, the 5-year survival was 60%. The 5-year survival was 100% for those with stage 0-I disease, 87% for stage II, and 42% for stage III. The 3-year survival was 14% for stage IV. Conclusion:Patients with male breast cancer presented at an older age, a later stage, and with earlier metastasis. Early metastasis and death increases with increasing stage. Poor prognosis correlates with late admission. Data from different centers should be compiled and reviewed in order to determine a specific treatment protocol for male breast cancer; each paper published reveals new data.

show abstract

Incidence and Outcome of Male Breast Cancer: An International Population-Based Study

Cited by 201 publications

References 26 publications

Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan

Male Breast Cancer: a 24 Year Experience of a Tertiary Care Hospital in Pakistan

High proliferation is associated with inferior outcome in male breast cancer patients

The Management and Outcomes of Male Breast Cancer

Contact Info

Product

Resources

About